LCP1与免疫透相关:三阴性乳腺癌的预后标志物

Shuaikang Pan1,2, Mengting Wan1, Hongwei Jin1

  • 1Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.

BMC immunology
|July 8, 2024
PubMed
概括

淋巴细胞细胞蛋白1 (LCP1) 在三阴性乳腺癌 (TNBC) 中表达更高. 高LCP1水平与更好的生存和免疫细胞透相关,这表明它有可能作为TNBC免疫疗法的预后生物标志物.